Purpose: We report the duration of response to UGN-102 treatment in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) 24 months after achieving complete response (CR). Materials and Methods: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with biopsy-proven recurrent LG-IR-NMIBC. Patients received 6 once-weekly intravesical instillations of UGN-102. Patients underwent cystoscopy, urine cytology tes

ABSTRACT Objective To define mild, moderate and severe symptom categories of the neurogenic bladder symptom score (NBSS) and NBSS-short form (SF), and to calculate the minimal clinically important difference (MCID) of the NBSS-SF. Methods We used existing datasets from the original NBSS validation study (n = 230 patients with spinal cord injury (SCI), multiple sclerosis, and spina bifida), and a large cross-sectional study of people with SCI (n = 1479) who completed the NBSS.

Abstract Introduction Differences in how Medicare advantage prescription drug plans (MA-PDs) and stand-alone prescription drug plans (PDPs) are financed may contribute to fewer coverage options for traditional Medicare beneficiaries. The Inflation Reduction Act (IRA) capped annual out-of-pocket spending and reduced government reinsurance, thereby placing more cost responsibility on plans and manufacturers and potentially further limiting coverage. Methods This study draws on